Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Preiss

Showing results (131-140 of 160) with videos related to

Pageof 16
Sort By:
Stroke|August 1, 2013
Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trialDavid Preiss, Thomas D Giles, Laine E Thomas, et al.
BMJ Open|December 4, 2012
Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trialDavid Preiss, Laine E Thomas, Jie-Lena Sun, et al.
European Journal of Heart Failure|March 11, 2015
Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fractionSøren L Kristensen, Pardeep S Jhund, Lars Køber, et al.
Circulation|January 6, 2017
Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction)Søren L Kristensen, Ulrik M Mogensen, Pardeep S Jhund, et al.
Clinical Cardiology|March 7, 2016
Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) TrialSteven E Nissen, Ricardo E Dent-Acosta, Robert S Rosenson, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 25, 2018
Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart AssociationConnie B Newman, David Preiss, Jonathan A Tobert, et al.
Diabetes Care|March 8, 2020
Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart DiseaseGregory G Schwartz, Lawrence A Leiter, Christie M Ballantyne, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 15, 2024
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
JAMA|April 4, 2016
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical TrialSteven E Nissen, Erik Stroes, Ricardo E Dent-Acosta, et al.
Circulation. Heart Failure|January 13, 2016
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure TrialSøren L Kristensen, David Preiss, Pardeep S Jhund, et al.
Pageof 16

Showing results (131-140 of 160) with videos related to

Sort By:
Pageof 16
Stroke|August 1, 2013
Predictors of stroke in patients with impaired glucose tolerance: results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trialDavid Preiss, Thomas D Giles, Laine E Thomas, et al.
BMJ Open|December 4, 2012
Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trialDavid Preiss, Laine E Thomas, Jie-Lena Sun, et al.
European Journal of Heart Failure|March 11, 2015
Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fractionSøren L Kristensen, Pardeep S Jhund, Lars Køber, et al.
Circulation|January 6, 2017
Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction)Søren L Kristensen, Ulrik M Mogensen, Pardeep S Jhund, et al.
Clinical Cardiology|March 7, 2016
Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) TrialSteven E Nissen, Ricardo E Dent-Acosta, Robert S Rosenson, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 25, 2018
Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart AssociationConnie B Newman, David Preiss, Jonathan A Tobert, et al.
Diabetes Care|March 8, 2020
Dalcetrapib Reduces Risk of New-Onset Diabetes in Patients With Coronary Heart DiseaseGregory G Schwartz, Lawrence A Leiter, Christie M Ballantyne, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 15, 2024
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trialKaitlin J Mayne, Rebecca J Sardell, Natalie Staplin, et al.
JAMA|April 4, 2016
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical TrialSteven E Nissen, Erik Stroes, Ricardo E Dent-Acosta, et al.
Circulation. Heart Failure|January 13, 2016
Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure TrialSøren L Kristensen, David Preiss, Pardeep S Jhund, et al.
Pageof 16